glp 1 agonists and sglt2 inhibitors Cardiorenal Protection: Potential of GLP-1 Receptor in the Treatment of Type 2 Diabetes | Diabetes Therapy SGLT2 Inhibitors and GLP-1 Receptor
Description
Similarly, the trend remained unchanged in the stratified analysis according to the status of comorbidities, including MASH, LC, heart failure, T2D and CKD
21,25 A recent communication from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee indicated that the current evidence does not support a causal link between GLP-1 RA and thyroid cancer, nor does it warrant alterations to the product information
doi: 10.3390/ph3082398, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 32
A BMI of 27 kg/m2 or higher in case of any obesity-related comorbidities, such as type 2 diabetes or cardiovascular diseases like hypertension
According to Mayo Clinic, Gastroparesis is a condition that affects the normal movement of the muscles in your stomach
Dietary modifications should focus on evidence-based patterns recommended by NICE and Diabetes UK
